Evidence map›Paper›PMID 40600457›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Nature-Inspired Nanostructures from Multiple-Species Biomembranes: Rational Engineering and Therapeutic Applications in Tumor-Targeted Nanomedicine.

Xiaodan Wei, Chi Wang, Xiangyan Chen, Yuanyuan Zhu, Mei Yang, Ningxi Li, Honglin Huang, Guangjian Zhang, Mingzhen Zhang, Yiyao Liu and 1 more

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaodan WeiDepartment of Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
Chi WangDepartment of Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
Xiangyan ChenDepartment of Otorhinolaryngology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, P.R. China.
Yuanyuan ZhuDepartment of Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
Mei YangDepartment of Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
Ningxi LiMianyang Key Laboratory of Anesthesia and Neuroregulation, Department of Anesthesiology, Mianyang Central Hospital, Mianyang, Sichuan, 621000, P. R. China.
Honglin HuangDepartment of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, P.R. China.
Guangjian ZhangDepartment of Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
Mingzhen ZhangSchool of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
Yiyao LiuDepartment of Otorhinolaryngology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, P.R. China.ORCID https://orcid.org/0000-0002-7222-739X
Rui GaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.

Funding

Establishment and Clinical Study of a Novel Standardized Whole-Course Management Model for Elderly Lung Cancer Surgical Patients 2023ZD0501805Institutional Foundation of the First Affiliated Hospital of Xi'an Jiaotong University 2024-QN-24Key Industry Innovation Chain of Shaanxi 2025TD-08National Natural Science Foundation of China 12132004National Natural Science Foundation of China 32471367National Natural Science Foundation of China 82472021Postdoctoral Fellowship program (Grade C) of China Postdoctoral Science Foundation GZC20241369Shaanxi Key Industrial Chains 2024SF-ZDCYL-02-07Shaanxi Province Postdoctoral Science Foundation 2024BSHSDZZ040Shaanxi Provincial Administration of Traditional Chinese Medicine Research Project 2022-SLRH-LJ-009Shaanxi Provincial Young Leading Talent in Scientific and Technological Innovation KSQYC202303
6 · The paper itself

Abstract

The advent of nanomedicine is profoundly revolutionizing conventional paradigms in cancer therapeutics. Selected formulations encompassing lipid nanoparticles and polymeric nanoparticles have already attained regulatory approval for clinical treatment. Nonetheless, achieving precise spatiotemporal control of exogenous nanomedicine within intricate physiological environments remains a formidable challenge. Drawing inspiration from evolutionarily optimized natural biological architectures, the development of biomembrane-derived nanostructures with unique biological activities provides a new impetus for designing personalized antitumor drugs. Biomembrane-derived constituents, particularly cell membrane, extracellular vesicles, and other bioactive payloads, have inherited their precise targeting, specific tumor killing, and dynamic tumor immunosuppressive microenvironments remodeling properties in antitumor intervention. Here, the diverse biomembrane engineering strategies to equip the biomembrane with plentiful functionalities are highlighted. Moreover, the cutting-edge innovations of mammalian cells/bacteria/plants-derived biomembrane nanostructures and their applications for advancing cancer nanomedicine development are systematically reviewed. Finally, the current challenges and future opportunities are proposed to realize the whole potential of biomembrane nanomedicine toward clinical transformation.

Indexed as

Antineoplastic AgentsNanomedicineNanostructuresNeoplasmsAnimalsCell MembraneDrug Delivery SystemsHumansNanoparticlesTumor MicroenvironmentAntineoplastic Agentsantitumor therapybiomembranecell membranesextracellular vesiclesnanostructures

Identifiers

PMID40600457
PMCPMC12412495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.